TrialAnnals of the rheumatic diseases2023

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).

Roy M Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.